Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Smith & Nephew Snats ( (SNN) ).
On November 11, 2025, Smith & Nephew plc announced the vesting of 3,016 restricted shares awarded to CEO Deepak Nath under an agreement from April 2022. A portion of these shares was sold to meet tax obligations, reflecting the company’s adherence to regulatory requirements and impacting its financial disclosures. This transaction, conducted on the London Stock Exchange, underscores the company’s commitment to transparent governance and may influence stakeholder perceptions regarding executive compensation practices.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc operates in the medical technology industry, focusing on the development and manufacturing of advanced medical devices. The company’s primary products include orthopedics, sports medicine, and wound management solutions, serving a global market with a strong emphasis on innovation and quality.
Average Trading Volume: 657,460
Technical Sentiment Signal: Buy
Current Market Cap: $14.16B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.